ProfileGDS5678 / 1415816_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 95% 95% 95% 96% 95% 95% 95% 95% 96% 96% 96% 96% 96% 96% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.6053695
GSM967853U87-EV human glioblastoma xenograft - Control 28.5492795
GSM967854U87-EV human glioblastoma xenograft - Control 38.5134795
GSM967855U87-EV human glioblastoma xenograft - Control 48.8478796
GSM967856U87-EV human glioblastoma xenograft - Control 58.5723795
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.1836395
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 28.2589695
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.5958895
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.8313196
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.6836896
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.6800496
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.744496
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.8446496
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.7885696